3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Breast
1
Conditions
Sarcoma
6
Triple Negative Breast Neoplasms
2
Pathologic Complete Response
2
Osteosarcoma
2
Hemangiosarcoma
2
Breast Neoplasms
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Rectal Neoplasms
1
Patient Compliance
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Esophageal Neoplasms
1
Endometrial Clear Cell Adenocarcinoma
1
Disease Progression
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Standard of Care
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT04055220
2026-02-17
REGOSTA
Centre Leon Berard
Phase NA
Recruiting
168 enrolled